Health Care • Biotechnology: Pharmaceutical Preparations
$4.22 ▲ +0.00
(0.00%)
MKT CAP: $81.6M • VOL: 2.32M
52W L $4 52W H $13
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
CRBP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$85.3M | -$48.7M | -$45.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$78.5M | -$40.2M | -$44.6M |
| EBITDA (Normalized) | -$85.3M | -$48.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$64.5M | -$41.8M | -$36.1M |
| Capital Expenditures (CapEx) | $7.0K | $0 | — |
| Free Cash Flow (FCF) | -$64.5M | -$41.8M | -$36.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -30.7% | — |
| Cash & Short-Term Equivalents | $28.5M | $17.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $147.5M | $142.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRBP.